J07BN04 - Covid-19, Protein Subunit

Propably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the protein subunit Covid-19 vaccine, no porphyrinogenic effects are expected.

Chemical description

Protein subunit vaccine.

Therapeutic characteristics

Indicated for preventing coronavirus disease 2019 (COVID-19) in individuals aged 12 years and older. It is administered by intramuscular injections.

Metabolism and pharmacokinetics

Vaccines are not metabolized by the cytochrome P450 system.

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BN or go back.

References

#	Citation details	PMID
*	Government bodies
1.	European Medicines Agency (EMA). SmPC Nuvaxovid.
2.	Norwegian institute of public health. Vaccines and vaccination.

Citation details

PMID

Government bodies

European Medicines Agency (EMA). SmPC Nuvaxovid.

Norwegian institute of public health. Vaccines and vaccination.

Tradenames

Show more details and information about the listed tradenames

Bimervax · Nuvaxovid

Bimervax · Nuvaxovid · Vidprevtyn Beta

Bimervax · Nuvaxovid

Nuvaxovid

Bimervax · Nuvaxovid

Nuvaxovid

Bimervax · Nuvaxovid

Bimervax · Nuvaxovid · Vidprevtyn Beta

Nuvaxovid · VidPrevtyn

Nuvaxovid · VidPrevtyn Beta

Vaccines

In cooperation with Ipnet